One-Offs Boost Japan's Top Firms In Mixed Q1
Pandemic Impact Limited
Executive Summary
Japan's top pharma firms benefited in several cases from one-off factors in what was a generally positive fiscal first quarter, but most full-year guidance remains unchanged for now.
You may also be interested in...
Coronavirus Update: Japan Approves Antibody Cocktail In Short Order
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.